The Pro Medicus Ltd (ASX: PME) share price has been one of the hardest-hit over the past year, down 56%, as the chart below shows.
But the medical imaging and services software business may have been oversold, according to experts. For starters, we should remember that the business has very defensive clients including hospitals, imaging centres and healthcare groups, so demand for services remains strong year to year.
The company has a pleasing outlook for both revenue and profit growth, which could bode very well to regain investor confidence. Let’s look at how undervalued the business could be.
Pro Medicus share price target
A share price target is where analysts think the share price could go within the next 12 months. But, it’s just an analyst’s estimate based on various factors (including the company’s fundamentals) â it’s not a guaranteed return.
According to CMC Invest, there have been eight ratings on the business within the last three months. Of those ratings, seven were buys, and one was a hold.
The average price target of those eight ratings is $196.73, suggesting a possible rise of 61% in the next year from where it is at the time of writing.
The most exciting price target is $241.89. This suggests the Pro Medicus share price could almost double within the next year.
At the other end of the spectrum, the lowest price target is $143.14. This still suggests a possible rise of 17%.
Valuation
Let’s also look at the price/earnings (P/E) ratio because it’s important to consider whether the company is attractive or not, bearing in mind its potential earnings growth.
It’s hard to know how much AI competitors will affect the software industry in the coming years, but analysts are still positive on the company’s potential.
According to the projection on CMC Invest, the business is forecast to generate earnings per share (EPS) of $1.372 in FY26 and $1.863 in FY27.
That means it’s valued at 89x FY26’s estimated earnings and 65x FY27’s estimated earnings. The projection also suggests that the business could grow EPS by 35.8% year-over-year in FY27.
If the company continues winning new customers (and renewing contracts on better terms), and retaining an underlying operating profit (EBIT) margin above 70%, then I think the company’s net profit could rise significantly from here. This could justify the most optimistic analysts’ projection.
The post How much could the Pro Medicus share price rise in the next year? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Pro Medicus shares jump as massive US contract win turns heads
- Pro Medicus inks $90m contract
- 2 beaten-down ASX shares to hold until 2036
- 3 amazing ASX growth shares to buy and hold forever
- ASX tech shares vs. ATEC ETF: How they fared during sector downturn
Motley Fool contributor Tristan Harrison has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.